Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Soleno Therapeutics Inc (SLNO)

Soleno Therapeutics Inc (SLNO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 94,787
  • Shares Outstanding, K 44,711
  • Annual Sales, $ 0 K
  • Annual Income, $ -30,770 K
  • 60-Month Beta 0.45
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 9.85

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.20
  • Number of Estimates 1
  • High Estimate -0.20
  • Low Estimate -0.20
  • Prior Year -0.31
  • Growth Rate Est. (year over year) +35.48%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.55 +36.77%
on 06/09/20
3.54 -40.11%
on 06/08/20
-1.14 (-34.97%)
since 06/05/20
3-Month
1.55 +36.77%
on 06/09/20
4.39 -51.71%
on 05/21/20
-0.35 (-14.17%)
since 04/07/20
52-Week
1.18 +79.66%
on 10/23/19
4.39 -51.71%
on 05/21/20
-0.42 (-16.54%)
since 07/05/19

Most Recent Stories

More News
Soleno Therapeutics Added to Russell 3000(R) Index

Soleno Therapeutics, Inc. ("Soleno") (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it has been added...

SLNO : 2.12 (+1.44%)
Soleno Therapeutics Announces Closing of $57.5 Million Public Offering of Common Stock, Including the Full Exercise of Underwriters' Option to Purchase Additional Shares

Soleno Therapeutics, Inc. (Nasdaq: SLNO), ("Soleno" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today the closing...

SLNO : 2.12 (+1.44%)
Translate Bio (TBIO) in Focus: Stock Moves 11.7% Higher

Translate Bio (TBIO) saw a big move last session, as its shares jumped nearly 12% on the day, amid huge volumes.

TBIO : 17.54 (+0.80%)
SLNO : 2.12 (+1.44%)
Soleno Therapeutics Announces Pricing of $50 Million Public Offering of Common Stock

Soleno Therapeutics, Inc. (Nasdaq:SLNO), ("Soleno" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today the pricing...

SLNO : 2.12 (+1.44%)
Soleno Therapeutics Announces Proposed Public Offering of Common Stock

Soleno Therapeutics, Inc. (Nasdaq: SLNO), ("Soleno" or the "Company"), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that...

SLNO : 2.12 (+1.44%)
Soleno (SLNO) Looks Good: Stock Adds 6.8% in Session

Soleno (SLNO) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

SLNO : 2.12 (+1.44%)
ATXI : 9.70 (-4.15%)
Soleno Therapeutics, Inc. (SLNO) Upgraded to Strong Buy: What Does It Mean for the Stock?

Soleno Therapeutics, Inc. (SLNO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term....

SLNO : 2.12 (+1.44%)
Soleno Therapeutics Announces Top-line Results from Phase III Trial of DCCR for Treatment of Prader-Willi Syndrome

Study Did Not Meet Statistical Significance for Primary Endpoint, but Showed Significant Improvements in Prespecified Subgroup with Severe Hyperphagia

SLNO : 2.12 (+1.44%)
Implied Volatility Surging for Soleno Therapeutics (SLNO) Stock Options

Investors need to pay close attention to Soleno Therapeutics (SLNO) stock based on the movements in the options market lately.

SLNO : 2.12 (+1.44%)
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2020 Financial Results

Soleno Therapeutics, Inc. ("Soleno") (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and...

SLNO : 2.12 (+1.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Trade SLNO with:

Business Summary

Soleno Therapeutics Inc. is a healthcare company. It develops and commercializes diagnostics, devices and therapeutics addressing unmet medical needs. The Company offers products consists of CoSense end-tidal carbon monoxide Monitor, NeoPIP Infant Resuscitator and Accessories and Serenz Nasal Relief....

See More

Key Turning Points

2nd Resistance Point 2.34
1st Resistance Point 2.23
Last Price 2.12
1st Support Level 2.06
2nd Support Level 2.00

See More

52-Week High 4.39
Fibonacci 61.8% 3.16
Fibonacci 50% 2.78
Fibonacci 38.2% 2.41
Last Price 2.12
52-Week Low 1.18

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar